The humira drug market size is expected to see strong growth in the next few years. It will grow to $14.19 billion in 2029 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to biosimilar market entry, healthcare policy changes, focus on cost-effectiveness, research and development investments, precision medicine and personalized treatments. Major trends in the forecast period include real-world evidence generation, expanded use in pediatric populations, shift towards self-administered medications, value-based pricing models, targeted therapies development.
An anticipated increase in the incidence rate of autoimmune diseases is expected to drive growth in the Humira drug market in the future. Autoimmune diseases occur when the body's immune system mistakenly attacks and damages healthy tissues and cells. Humira is utilized to alleviate pain and inflammation associated with various autoimmune conditions; thus, a rise in these diseases leads to increased demand for Humira. For example, in March 2024, the National Health Council, a U.S.-based non-profit organization, reported that autoimmune diseases affect approximately 50 million Americans. However, due to the complexities of diagnosing these diseases, this figure is likely underestimated. Alarmingly, the prevalence of autoimmunity is approaching epidemic levels, with some studies indicating an annual increase of 3-12%. Consequently, the rising incidence of autoimmune diseases will fuel the growth of the Humira drug market.
The humira drug market is also witnessing significant growth due to broad regulatory approvals granted across various countries and regions. Regulatory endorsements by governments worldwide enhance the accessibility of the humira drug globally. For instance, in April 2023, the European Commission granted marketing authorization for a citrate-free high concentration formulation (HCF) of the biosimilar Hyrimoz (adalimumab) in the European Union. The expansive regulatory approvals for Humira contribute significantly to the ongoing growth of the humira drug market.
Product innovation stands out as a key trend in the humira drug market, with major companies developing new biologics and biosimilars to maintain their market positions. In April 2023, Sandoz, a Switzerland-based pharmaceutical company, introduced the Biosimilar Hyrimoz (adalimumab), featuring a citrate-free high-concentration formulation (HCF) approved by the European Commission. This innovative formulation provides a 50% reduction in injection volume and offers an improved experience for patients with various diseases, including rheumatic diseases and Crohn's disease.
Major companies in the humira drug market are actively focusing on the development of biosimilars for humira drugs. This strategic approach aims to enhance the cost-effectiveness of humira drugs by producing specialty biosimilars tailored for these medications. In October 2023, Boehringer Ingelheim, a Germany-based pharmaceutical company, launched a biosimilar of Humira, approved by the US Food and Drug Administration as interchangeable with the original product, offering a more cost-effective alternative.
In August 2023, CVS Health Corporation, a US-based pharmacy company, entered into a partnership with Sandoz Group AG, a Switzerland-based pharmaceuticals company. This collaboration aims to create a nearly identical drug at a significantly lower cost than the popular arthritis treatment Humira. The partnership establishes Cordavis, a new subsidiary of Novartis, with a primary focus on ensuring the supply of novel biosimilar medications. This strategic move positions CVS Health to compete effectively in the biosimilars market, projected to reach $100 billion in sales over the next six years.
Major companies operating in the humira drug market include Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Fresenius Kabi AG, Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sandoz International GmbH, Hikma Pharmaceuticals PLC, Celltrion Healthcare Co. Ltd., Cadila Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Mochida Pharmaceutical Co. Ltd., Innovent Biologics Inc., Biocad Biopharmaceutical Company, Shanghai Henlius Biotech Inc., Glenmark Pharmaceuticals Ltd., Samsung Bioepis Co Ltd., Hetero Healthcare Ltd., Coherus BioSciences Inc., CinnaGen Co., Alvotech Holdings S.A, Reliance Life Sciences Private Limited, Momenta Pharmaceuticals Inc., Bio-Thera Solutions Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., BioXpress Therapeutics SA, Alteogen Inc., Prestige BioPharma Pte. Ltd.
North America was the largest region in the humira drug market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the humira drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the humira drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Humira, or adalimumab, is an injectable medication prescribed for the treatment of rheumatoid arthritis and other related conditions. These drugs are utilized to alleviate pain and reduce swelling associated with various types of arthritis.
The primary forms of Humira drugs are Humira syringes and Humira pens. Humira syringes are a form of treatment specifically used for progressive rheumatoid arthritis. The diverse applications of Humira include treating conditions such as ankylosing spondylitis, rheumatoid arthritis, Crohn's disease, and others. These drugs are employed by various end-users, including hospitals, specialty clinics, and other healthcare facilities.
The humira drugs market research report is one of a series of new reports that provides humira drugs market statistics, including humira drugs industry global market size, regional shares, competitors with a humira drugs market share, detailed humira drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the humira drugs industry. This humira drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The humira drug market consists of sales of single-dose pen, a single-dose prefilled syringe, and a single-dose vial of liquid solution. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
Executive Summary
Humira Drug Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on humira drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for humira drug? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The humira drug market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Humira Syringe; Humira Pen2) By Application: Ankylosing Spondylitis; Rheumatoid Arthritis; Crohn's Disease; Other Applications
3) By End-Users: Hospitals; Specialty Clinics; Other End-Users
Subsegments:
1) By Humira Syringe: Pre-Filled Syringe; Disposable Syringe2) By Humira Pen: Auto-Injector Pen; Pre-Filled Injection Pen
Key Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; Fresenius Kabi AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- Merck & Co. Inc.
- AbbVie Inc.
- Novartis AG
- Fresenius Kabi AG
- Amgen Inc.
- Boehringer Ingelheim International GmbH
- Viatris Inc.
- Sandoz International GmbH
- Hikma Pharmaceuticals PLC
- Celltrion Healthcare Co. Ltd.
- Cadila Pharmaceuticals Ltd.
- Torrent Pharmaceuticals Ltd.
- Mochida Pharmaceutical Co. Ltd.
- Innovent Biologics Inc.
- Biocad Biopharmaceutical Company
- Shanghai Henlius Biotech Inc.
- Glenmark Pharmaceuticals Ltd.
- Samsung Bioepis Co Ltd.
- Hetero Healthcare Ltd.
- Coherus BioSciences Inc.
- CinnaGen Co.
- Alvotech Holdings S.A
- Reliance Life Sciences Private Limited
- Momenta Pharmaceuticals Inc.
- Bio-Thera Solutions Ltd.
- Fujifilm Kyowa Kirin Biologics Co. Ltd.
- BioXpress Therapeutics SA
- Alteogen Inc.
- Prestige BioPharma Pte. Ltd.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | February 2025 |
Forecast Period | 2025 - 2029 |
Estimated Market Value ( USD | $ 10.43 Billion |
Forecasted Market Value ( USD | $ 14.19 Billion |
Compound Annual Growth Rate | 8.0% |
Regions Covered | Global |
No. of Companies Mentioned | 30 |